Mariner
NBIX icon

Mariner’s Neurocrine Biosciences NBIX Stock Holding History

Mariner’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1M Sell
155,039
-5,830
-4% -$865K 0.03% 414
2026
Q1 		$21.2M Buy
160,869
+64,856
+68% +$8.61M 0.02% 451
2025
Q4 		$13.6M Buy
96,013
+41,221
+75% +$5.97M 0.02% 573
2025
Q3 		$7.69M Buy
54,792
+27,759
+103% +$3.76M 0.01% 736
2025
Q2 		$3.4M Buy
27,033
+9,021
+50% +$1.03M ﹤0.01% 1038
2025
Q1 		$1.99M Sell
18,012
-2,627
-13% -$333K ﹤0.01% 1252
2024
Q4 		$2.82M Buy
20,639
+3,857
+23% +$477K ﹤0.01% 1038
2024
Q3 		$1.93M Sell
16,782
-3,107
-16% -$426K ﹤0.01% 1207
2024
Q2 		$2.74M Buy
19,889
+395
+2% +$54.2K 0.01% 954
2024
Q1 		$2.69M Buy
19,494
+2,397
+14% +$327K 0.01% 968
2023
Q4 		$2.25M Buy
17,097
+6,119
+56% +$704K 0.01% 1008
2023
Q3 		$1.24M Buy
10,978
+670
+6% +$70.6K ﹤0.01% 1212
2023
Q2 		$972K Buy
10,308
+395
+4% +$38.6K ﹤0.01% 1331
2023
Q1 		$1M Sell
9,913
-684
-6% -$71.2K ﹤0.01% 1274
2022
Q4 		$1.27M Sell
10,597
-1,183
-10% -$139K ﹤0.01% 1129
2022
Q3 		$1.25M Buy
11,780
+129
+1% +$13.1K 0.01% 956
2022
Q2 		$1.14M Buy
11,651
+855
+8% +$78.9K ﹤0.01% 864
2022
Q1 		$1.01M Buy
+10,796
New +$915K ﹤0.01% 927
2019
Q3 		– Sell
-2,637
Closed -$223K – 923
2019
Q2 		$223K Sell
2,637
-17
-0.6% -$1.4K ﹤0.01% 1006
2019
Q1 		$234K Buy
+2,654
New +$222K ﹤0.01% 907

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mariner's NBIX Position: Q2 2026 in Review

Mariner reduced its Neurocrine Biosciences (NBIX) stake by 3.6% in Q2 2026, selling an estimated $865K and leaving 155,039 shares worth $26.1M. The position accounts for 0.03% of the portfolio, ranked #414.

Mariner first reported a position in NBIX in Q1 2019 and has held it in 20 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Mariner held 155,039 shares of Neurocrine Biosciences worth $26.1M as of Q2 2026.
  • Mariner sold 5,830 Neurocrine Biosciences shares in Q2 2026, an estimated $865K.
  • Neurocrine Biosciences made up 0.03% of Mariner's portfolio in Q2 2026, its #414 holding.
  • Mariner first reported a position in Neurocrine Biosciences in Q1 2019 and has held it in 20 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.